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Abstract
Background: Surveys on prescription patterns for antipsychotics in the Scandinavian public health system are
scarce despite the prevalent use of these drugs. The clinical differences between antipsychotic drugs are mainly
in the areas of safety and tolerability, and international guidelines for the treatment of schizophrenia offer rational
strategies to minimize the burden of side effects related to antipsychotic treatment. The implementation of
treatment guidelines in clinical practice have proven difficult to achieve, as reflected by major variations in the
prescription patterns of antipsychotics between different comparable regions and countries. The objective of this
study was to evaluate the practice of treatment of schizophrenic patients with antipsychotics at discharge from
acute inpatient settings at a national level.
Methods: Data from 486 discharges of patients from emergency inpatient treatment of schizophrenia were
collected during a three-month period in 2005; the data were collected in a large national study that covered 75%
of Norwegian hospitals receiving inpatients for acute treatment. Antipsychotic treatment, demographic variables,
scores from the Global Assessment of Functioning and Health of the Nation Outcome Scales and information
about comorbid conditions and prior treatment were analyzed to seek predictors for nonadherence to guidelines.
Results: In 7.6% of the discharges no antipsychotic treatment was given; of the remaining discharges, 35.6% were
prescribed antipsychotic polypharmacy and 41.9% were prescribed at least one first-generation antipsychotic
(FGA). The mean chlorpromazine equivalent dose was 450 (SD 347, range 25–2800). In the multivariate
regression analyses, younger age, previous inpatient treatment in the previous 12 months before index
hospitalization, and a comorbid diagnosis of personality disorder or mental retardation predicted antipsychotic
polypharmacy, while previous inpatient treatment in the previous 12 months also predicted prescription of at
least one FGA.
Conclusion: Our national survey of antipsychotic treatment at discharge from emergency inpatient treatment
revealed antipsychotic drug regimens that are to some degree at odds with current guidelines, with increased risk
of side effects. Patients with high relapse rates, comorbid conditions, and previous inpatient treatment are
especially prone to be prescribed antipsychotic drug regimens not supported by international guidelines.
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The clinical differences between antipsychotic drugs are
mainly in the areas of safety and tolerability. International
guidelines for the treatment of schizophrenia [1-4] offer
rational strategies to minimize the burden of side effects
related to antipsychotic treatment. These recommenda-
tions may be considered according to three dimensions:
first-versus second-generation antipsychotics; antipsy-
chotic mono-versus polypharmacy; and optimal dosing of
antipsychotics. The second-generation antipsychotics
(SGAs) as a group are less associated with extrapyramidal
symptoms (EPS) and hyperprolactinemia compared with
the older first-generation drugs (FGAs), and are recom-
mended by most guidelines as first-line therapy for schiz-
ophrenia [3]. Antipsychotic monotherapy is generally
recommended, and most guidelines converge on a recom-
mendation that doses should be between 300 and 1000
chlorpromazine equivalents [5] in order to achieve the
important goal of maximum reduction of positive symp-
toms, while avoiding EPS and use of anticholinergic med-
ication [6].
The implementation of treatment guidelines in clinical
practice has proven difficult to achieve [7], reflected by
major variations in the prescription patterns of antipsy-
chotics between different comparable regions and coun-
tries [8-10]. Prescribing a drug regime with poorer
tolerability may ultimately increase the risk of relapse, as
an association between increasing side effects and poorer
drug adherence has been shown [11]. The goal of avoiding
relapses and hospital admissions for patients with schizo-
phrenia is also of major importance from a cost-effective-
ness perspective as readmissions represent one of the
largest contributors to total treatment costs [12]. Surveys
of prescription patterns for antipsychotics in the Scandi-
navian public health system are scarce despite the preva-
lent use of these drugs. Studies addressing issues related to
optimal antipsychotic treatment, as well as detection of
predictors of noncompliance to guidelines, are important.
The psychiatric emergency wards often set the stage for the
treatment of schizophrenia and offer an important oppor-
tunity to investigate the prescription patterns of antipsy-
chotics.
The aims of this study were to evaluate the Norwegian
practice of antipsychotic treatment of patients with schiz-
ophrenia at discharge from acute inpatient settings, com-
pared with the international recommended guidelines of
monotherapy, choice of antipsychotics, and dosing. In
addition, we wanted to study whether demographic or
clinical factors at admission predicted noncompliance to
guideline recommendations.
Methods
The data were collected in the Norwegian Multicenter
Study in Acute Psychiatry (MAP) [13] conducted by the
Network for Evaluation of Acute Psychiatry, coordinated
by SINTEF Health Research and financed in part by the
Norwegian Directorate of Health and Social Affairs. The
study was approved by the Regional Ethical Committee,
the Norwegian Directorate of Health and Social Affairs,
and the Norwegian Data Inspectorate. The Norwegian
psychiatric inpatient system receives mostly acutely
admitted patients to emergency wards at psychiatric hos-
pitals or departments at general hospitals. The majority of
all admitted patients are discharged from these wards to
outpatient treatment in the psychiatric specialist system or
to treatment by general practitioners. Many of the patients
with schizophrenia or major affective disorders are trans-
ferred to other specialized hospital wards or community
mental health centers for further inpatient treatment.
MAP is a cross-sectional observational study that included
19 hospitals with 37 inpatient wards receiving acutely
admitted patients. The emergency wards were distributed
in the five health regions of Norway, and the participating
hospitals were university hospitals and regional and local
psychiatric hospitals. A total of 3506 consecutive hospital
admissions were recorded during three months of 2005.
The 19 participating hospitals comprised approximately
75% of the Norwegian hospitals receiving patients for
acute psychiatric inpatient treatment. From this material
we have selected admissions with a diagnosis of schizo-
phrenia at discharge (some patients had more than one
admission and discharge in the study period). Data were
recorded at admission and discharge.
The data collected by MAP at admission and discharge
from emergency wards included demography, informa-
tion about treatment history, medication, and clinical
measures including the Global Assessment of Function-
Split Version (S-GAF) [14,15] and Health of the Nation
Outcome Scales (HoNOS) [16]. The rating on the scales
was performed by the resident who assessed the patient at
admission to the hospital, and training in HoNOS scoring
was conducted at all participating hospitals. HoNOS item
1 (overactive, aggressive, disruptive, or agitated behavior)
and HoNOS item 6 (hallucinations and delusions) were
dichotomized to 0 (scores of 0, 1, or 2) or 1 (scores of 3
or 4). Clinical diagnoses according to the ICD 10 [17]
were obtained from the medical records. Classification of
antipsychotics in FGAs or SGAs and the computation of
chlorpromazine-equivalent doses (CPZ) were done
according to the literature and listed in Table 1[18-24].
The Defined Daily Dose (DDD) is obtained from the
WHO Collaborating Centre for Drug Statistics Methodol-
ogy and is assumed to be the average maintenance dose
per day for a drug used for its main indication in
adults[22]. To focus on prescriptions intended to treat
psychotic symptoms, we excluded prescriptions of low-
potency FGAs in doses below 100 CPZ from the analyses
of prediction of polypharmacy and prediction of prescrip-
tion of at least one FGA at discharge.Page 2 of 9
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All regression analyses used methods for clustered obser-
vations (GEE) because some patients had more than one
hospitalization. For each drug, the change in prescriptions
between admission and discharge was tested by logistic
regression. The p values were adjusted for multiple com-
parisons with the Benjamini-Hochberg method.
Univariate and multivariate logistic regression analyses
with polypharmacy at discharge and use of at least one
FGA at discharge as dependent variables (after exclusion
of prescriptions of low-potency FGAs in doses below 100
CPZ) were conducted with the following independent
variables: age, sex, GAF severity of symptoms at admis-
sion, HoNOS items 1 and 6 (dichotomized) at admission,
inpatient and outpatient treatment during the immediate
12 months before admission (dichotomized), having a
remitting/chronic or first-episode condition, and having a
comorbid diagnosis of substance abuse, personality disor-
der, or mental retardation. However, in the logistic regres-
sion with use of at least one FGA at discharge as the
dependent variable, recurrent illness and a comorbid
diagnosis of mental retardation had to be excluded from
the analysis for stability reasons. As sensitivity analyses,
the analyses were repeated, including low-potency FGAs.
Results are presented as odds ratios with corresponding
95% confidence intervals and p values.
The relationship between dosage and the independent
variables above was analyzed using linear regression.
Results were presented with p values, and effects were
reported with unstandardized regression coefficients and
Table 1: Antipsychotic equivalent doses and Defined Daily Doses of common antipsychotics.
Drug Potency Ratio Antipsychotic equivalent doses. DDD5 (mg) Adm-route
FGA
Low-potency
Chlorpromazine (Largactil®) 1.0 300.0 300.0 O
Klorprotixene (Truxal ®) 2.0 150.02 300.0 O
Levomepromazine (Nozinan®) 1.0 300.05 300.0 O
Thioridazine (Melleril®) 1.0 300.01 300.0 O
Medium potency
Dixyrazine (Esucos®) 6.0 50.05 50.0 O
Perphenazine (Trilafon®) 12.5 24.01 30.0 O
Perphenazine decanoate (Trilafon depot®) 53.0 5.75 7.0 P
Prochlorperazine (Stemetil®) 6.7 45.01 100.0 O
Zuclopenthixol (Cisordinol®) 4.0 75.01 30.0 O
Zuclopenthixol decanoate (Cisordinol Depot®) 7.0 42.01 15.0 P
High-potency
Flupenthixol (Fluanxol®) 50.0 6.01 6.0 O
Flupenthixol decanoate (Fluanxol depot®) 70.0 4.21 4 4.0 P
Haloperidol (Haldol®) 33.0 9.01 8.0 O
Haloperidol decanoate (Haldol depot®) 50.0 6.01 4 3.3 P
SGA
Amisulpride (Solian®) 1.0 300.01 400.0 O
Aripiprazole (Abilify®) 13.3 22.53 15.0 O
Clozapine (Leponex®, Clozapine®) 1.0 300.01 300.0 O
Olanzapine (Zyprexa®) 20.0 15.03 10.0 O
Quetiapine (Seroquel®) 1.3 225.03 400.0 O
Risperidone (Risperdal®) 66.0 4.51 5.0 O
Risperidone long-acting injection (Risperdal Consta®) 100.0 3.06 1.8 P
Sertindole (Serdolect®) 18.8 16.05 16.0 O
Ziprazidone (Zeldox®) 1.6 180.03 80.0 O
1Bazire, S. (2005) Psychotropic Drug Directory 2005. [18]
2Davis, J. M. (1974) Dose equivalence of the antipsychotic drugs. J. Psychiatr. Res., 11, 65–69[19]
3Woods, S. W. (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry, 64, 663–667. [20]
4Kane, J. M., Aguglia, E., Altamura, A. C., et al (1998) Guidelines for depot antipsychotic treatment in schizophrenia. European 
Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur. Neuropsychopharmacol., 8, 55–66. [21]
5WHO Collaborating Centre for Drug Statistics Methodology (2005) ATC Index with DDDs. [22]
6 Bai YM et al, Equivalent Switching Dose From Oral Risperidone to Risperidone Long-Acting Injection: A 48-Week Randomized, Prospective, 
Single-Blind Pharmacokinetic Study. J Clin Psychiatry 2007;68:1218–1225. [24].
7Administration Route: O: oral, P: peroral.
The chlorpromazine equivalent doses of levomepromazine, dixyrazine, sertindol and perphenazine decanoate are not adequately defined in the 
literature, and chlorpromazine equivalent dose is calculated from the DDD.Page 3 of 9
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(university vs. other) and region of the hospitals, and use
of polypharmacy and at least one FGA were analyzed by
logistic regression. SPSS software, version 15 (SPSS, Chi-
cago, IL, USA) and R (The R Foundation for Statistical
Computing, Vienna, Austria) were used for the statistical
analyses.
Results
A total of 486 discharges of patients with a diagnosis of
schizophrenia were identified and selected from the MAP
database. The discharges were distributed among 412
patients where 352 patients had one hospitalization, 49
patients had two hospitalizations, eight patients had three
hospitalizations, and three patients had four hospitaliza-
tions in the acute inpatient units during the three-month
study period. The background variables are given in Table
2.
Olanzapine was the single most frequently prescribed
drug both at admission (25.1%) and at discharge
(29.0%), followed by risperidone, which was prescribed
in 19.1% of the discharges. There was a significant
increase in the prescription of olanzapine (p = 0.049) and
zuclopenthixol (p = 0.049) from admission to discharge
(see Table 3). Depot antipsychotics were prescribed in
35.6%, and clozapine was prescribed in 8.0% of the dis-
charges.
In 7.6% of the cases, no antipsychotic medication was pre-
scribed at discharge. In the remaining 449 discharges,
antipsychotic polypharmacy was used in 160 cases
(35.6%) and one or more FGA in 204 (41.9%) cases. In a
subanalysis with exclusion of FGA in doses below 100
CPZ, antipsychotic polypharmacy was prescribed in 112
cases (24.9%) and at least one FGA in 177 cases (36.4%).
Of the total of 449 discharges with antipsychotic treat-
ment, monotherapy was prescribed in 289 (64.4%) of the
cases; of these, 203 (45.2%) were treated with SGAs.
Among the 160 (35.6%) cases with polypharmacy, 29
(6.5%) were treated with combinations of two or more
FGAs; two or more SGAs were prescribed in 42 (9.4%)
cases; and in 89 cases (19.8%), a combination including
both FGA and SGA was prescribed. In 56 (12.3%) periods
for patients treated with antipsychotic polypharmacy, one
or more antipsychotics were started during the hospitali-
zation, combined with one or more antipsychotics
unchanged from admission to discharge. In 20 (4.5%)
cases, patients received clozapine in combination with
another SGA.
There were 15 cases with first-episode patients. Of these,
14 were treated with SGA monotherapy and one had a
combination of SGA with an FGA (25 mg levomepro-
mazine).
In seven of the nine discharges with a comorbid diagnosis
of mental retardation, an FGA was prescribed.
In the univariate analyses, predictors for antipsychotic
polypharmacy (excluding low-potency antipsychotics in
doses below 100 CPZ) were found to be younger age,
lower GAF-S score, recurrent illness, having had inpatient
treatment in the previous 12 months, a comorbid person-
ality disorder, and mental retardation. In the multivariate
analyses, younger age, inpatient treatment during the pre-
vious 12 months, and a comorbid diagnosis of a person-
ality disorder or mental retardation predicted
antipsychotic polypharmacy (See Table 4). In sensitivity
analysis including low-potency FGAs, only personality
disorder was significant (OR 7.16, p = 0.035). Female sex
and inpatient treatment in the previous 12 months were
found to be predictors for the prescription of at least one
FGA (excluding low-potency antipsychotics in doses
below 100 CPZ) at discharge in the univariate analyses. In
the multivariate analyses, only inpatient treatment in the
previous 12 months was found to predict FGA prescrip-
tion. In sensitivity analysis including low-potency FGAs,
personality disorders had to be excluded for stability rea-
Table 2: Background variables of patients with schizophrenia at discharge from acute wards (n = 486).
Sex (M/F) 297/189 (61.1%/38.9%)
Age 40.8 ± 13.5 (range 15-82)
Ethnic Norwegian 430 (88.5%)
First-episode illness 17 (3.5%)
S-GAF: severity of symptoms at admission 31.7 ± 10.2 (range 10–75)
S-GAF: severity of functioning at admission 33.5 ± 10.3 (range 10–75)
Aggression at admission (HoNOS 1) 86 (17.7%)
Delusions/hallucinations at admission (HoNOS 6) 291 (59.9%)
Outpatient treatment in the previous 12 months 258 (53.1%)
Inpatient treatment in the previous 12 months 341 (70.2%)
Comorbid diagnosis of drug use/addiction 55 (11.3%)
Comorbid personality disorder 8 (1.6%)
Comorbid diagnosis of mental retardation 9 (1.9%)
Transferred to further in-patient treatment at discharge 286 (59.5%)Page 4 of 9
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ing the previous 12 months was still the only significant
predictor (OR 1.93, p = 0.014).
Mean chlorpromazine equivalent dose at discharge was
450 CPZ (SD 347, range 25–2800) (see Table 3). In the
linear regression with dosage as the dependent variable,
lower age, delusions or hallucinations at admission,
recurrent illness, and inpatient treatment during the pre-
vious year were found to predict higher dosages.
There were significant regional differences in the use of
FGAs (p = 0.012), with more prevalent prescription of
FGAs in the southern (OR 3.21) and northern (OR 1.88)
regions compared with the eastern region. No similar rela-
tionship was observed for the use of intended polyphar-
Table 3: Prescription of antipsychotic drugs at admission and discharge, p-values of differences and chlorpromazine equivalent doses at 
discharge (n = 486).
Antipsychotic drug Admission N(%) Discharge
N(%)
Adjusted P-value for the difference* Chlorpromazine equivalent dose at 
discharge
mean (SD) range
FGA
Low-potency
Levomepromazine (Nozinan®) 31(6.4) 39(8.2) 0.248 87 (99) 10–400
Chlorpromazine (Largactil®) 29(6.0) 28(5.8) 0.793 171 (104) 4–400
Klorprotixene (Truxal ®) 13(2.7) 18(3.7) 0.501 250 (145) 111–667
Thioridazine (Melleril®) 1(0.2) 1(0.2) 75
Medium potency
Perphenazine (Trilafon®) 24(4.9) 17(3.5) 0.248 187 (121) 50–400
Perphenazine decanoate (Trilafon 
depot®)
37(7.6) 49(10.1) 0.049 488 (243) 203–1624
Perphenazine total number patients 60(12.4) 65(13.4) 0.537
Zuclopentixol (Cisordinol®) 15(3.1) 21(4.3) 0.501 58 (27) 28–128
Zuclopenthixol decanoate 
(Cisordinol Depot®)
39(8.0) 49(10.1) 0.247 115 (61) 34–357
Zuclopenthixol total number patients 51(10.5) 68(14.0) 0.049
Dixyrazine (Esucos®) 4(0.8) 6(1.2) 0.536 300 (300-300)
Prochlorperazine (Stemetil®) 1(0.2) 1(0.2) 1000
High-potency
Haloperidol (Haldol®) 8(1.7) 10(2.0) 0.613 144 (85) 33–267
Haloperidol decanoate (Haldol 
depot®)
6(1.2) 7(1.4) 0.524 400 (164) 179–714
Haloperidol total number patients 14(2.9) 15(3.1) 0.793
Flupenthixol (Fluanxol®) 2(0.4) 3(0.6) 0.537 266 (85) 33–267
Flupenthixol decanoate (Fluanxol 
depot®)
5(1.0) 6(1.2) 0.793 247 (129) 153–429
Flupentixol total number patients 7(1.4) 9(1.9) 0.613
SGA
Olanzapine (Zyprexa®) 122 (25.1) 141 (29.0) 0.049 350 (137) 100–800
Risperidone (Risperdal®) 39(8.0) 43(8.9) 0.613 234 (107) 67–467
Risperidone long-acting injection 
(Risperdal Consta®)
57(11.7) 62(12.8) 0.565 311 (94) 179–536
Risperidon total number patients 91 (18.7) 93 (19.1) 0.793
Quetiapine (Seroquel®) 42(8.6) 46(9.5) 0.613 690 (533) 33–2800
Clozapine (Leponex®, Clozapine®) 37(7.6) 39(8.0) 0.524
Aripiprazole (Abilify®) 29(6.0) 30(6.2) 0.793 285 (94) 133–400
Ziprazidone (Zeldox®) 23(4.7) 24(4.9) 0.793 173 (90) 33–266
Amisulpride (Solian®) 11(2.3) 14(2.9) 0.537 600 (353) 100–1200
Sertindole (Serdolect®) 0(0) 1(0.2) missing
Total dose 450 (347) 25–2800
* Logistic regression for repeated observations (GEE). Exchangeable working correlations were used except (for stability reasons) for haloperidol 
depot and clozapine. For prochlorperazine and sertindol no tests were performed (at most one occasion of use at admission resp. discharge). The 
results were adjusted for multiple comparisions with Benjamini-Hochberg's method.Page 5 of 9
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differences between departments in university hospitals
and other hospitals.
Discussion
The present study revealed a total rate of 35.6% of polyp-
harmacy with antipsychotics and a rate of 41.9% first-gen-
eration antipsychotics at discharge. The antipsychotic
drug doses were within the recommended range in most
cases. An argument for not classifying low-potency FGAs
(levomepromazine, chlorpromazine, chlorprothixene,
and thioridazine) at low doses as antipsychotics exists if
the definition applies only to drugs prescribed for their
antipsychotic properties. It is not uncommon to use low-
potency FGAs as hypnosedatives, and in this regard, they
should not be classified as antipsychotics in the strict
sense of the term. In practice, however, such a definition
may prove difficult to validate retrospectively, as one
would need to know the intent of each prescribing clini-
cian to decide whether the drugs were prescribed for psy-
chosis per se. When low-potency FGAs in doses below 100
CPZ were excluded from the analyses in our sample, the
rate of polypharmacy was reduced to 24.9%, and the pro-
portion of periods prescribed at least one FGA was 36.4%.
Regarding antipsychotic polypharmacy, our findings are
comparable to those of other studies from Norway [8],
Denmark [25], Italy [26], and North America [27], in
which rates have ranged from 27% to 48%. A study from
Innsbruck reported only 12% antipsychotic polyphar-
macy at discharge; in this study low-potency FGAs were
excluded from the analyses. However, an increasing trend
of polypharmacy in recent years was also identified in that
study [28]. One previous study indicates that the level of
polypharmacy decreases when patients are followed-up
after discharge, and that part of polypharmacy can be an
intermediate situation [29]. The risk is, however, of long-
Table 4: Prediction of antipsychotic polypharmacy and prescription of at least one FGA at discharge. 
Prediction of FGA 95,0% C.I. for OR. Prediction of polypharmacy 95,0% 
C.I. for OR.
Variables OR
(Odds Ratio)
Lower Upper P-value OR
(Odds Ratio)
Lower Upper P-value
Age. 1.011 0.993 1.029 0.228 0.979 0.959 0.999 0.036
Female sex. 1.435 0.864 2.384 0.163 0.810 0.459 1.431 0.469
S-GAF:
severity of 
symptoms at 
admission.
0.992 0.971 1.013 0.449 0.984 0.960 1.007 0.181
Aggression at 
admission 
(HoNOS-1).
1.292 0.715 2.335 0.397 1.056 0.534 2.085 0.876
Delusions/
hallucinations at 
admission 
(HoN0S-6).
0.754 0.483 1.178 0.215 0.897 0.522 1.540 0.693
Recurrent illness. * * * * 4.731 0.572 39.168 0.150
Outpatient 
treatment in the 
previous 12 
months.
0.769 0.466 1.267 0.302 0.678 0.396 1.162 0.157
In-patient 
treatment in the 
previous 12 
months.
2.220 1.259 3.915 0.006 2.396 1.087 5.282 0.030
Comorbid 
diagnosis of drug 
misuse/addiction.
0.624 0.264 1.470 0.281 1.342 0.520 3.460 0.543
Comorbid 
diagnosis of 
personality 
disorder.
1.793 0.481 6.691 0.385 5.005 1.211 20.676 0.026
Comorbid 
diagnosis of 
mental 
retardation.
* * * * 13.968 1.341 145.485 0.027
Results from multivariate logistic regressions.
*Deleted from the model for model stability reasons.Page 6 of 9
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hospitalization because of sparse follow-up [30]. Nearly
5% of discharges have combinations of an SGA with cloz-
apine, which could be in line with guideline recommen-
dations in situations where clozapine monotherapy has
been tried without success. The 2006 Update of the Texas
Medication Algorithm for Schizophrenia recommends a
trial of combination with another antipsychotic when
there is partial or no response to clozapine, although the
results from randomized controlled trials in this field are
inconsistent [1]. Our data did not give answers to the
questions about treatment resistance; however, it is not
unlikely that the finding of a rate of polypharmacy of
35.6% (24.9% when low-potency FGAs in doses below
100 CPZ are excluded) reflects a high rate of treatment
resistance. This is also supported by the finding that
70.2% of patients had inpatient treatment in the previous
12 months. Bearing this in mind, the finding that only
8.0% of patients were prescribed clozapine can indicate a
prescription rate of clozapine that was too low. The find-
ing of a rate of 6.5% discharges with a combination of two
or more FGAs, and 19.8% with a combination of an FGA
and an SGA are indications of guideline noncompliance.
More than 40% of cases were prescribed at least one FGA
at discharge in our study (36.4% when FGAs in doses
below 100 CPZ were excluded). This is indeed a very high
rate compared with findings from the USA [31], while
comparable to previous findings from European studies
[8,26]. In the recent World Psychiatric Association Phar-
macopsychiatry Section statement on comparative effec-
tiveness of antipsychotics in the treatment of
schizophrenia [5], the goal to achieve a maximum reduc-
tion of positive symptoms while avoiding EPS or the use
of anticholinergic medication is emphasized, and while
the possibility of achieving this with FGA treatment is
noted, the probability of reaching this goal is more likely
with SGA treatment. A newly published review finds FGAs
to be associated with more extrapyramidal side effects
compared with SGAs [32], which is also the case for tar-
dive dyskinesias [33]. The high rate of FGA prescription in
our study could indicate suboptimal practice, leaving the
patients at higher risk of EPS than necessary. In addition
to this, the two most prescribed SGAs in our sample at dis-
charge were olanzapine (29.0%) and risperidone
(19.1%). These agents have both gained attention because
of their side-effect profiles that include weight gain, dysli-
pidemia, and diabetogenic effect for olanzapine, and
hyperprolactinemia and EPS for risperidone. The high
prescription rates of FGA and the SGAs olanzapine and
risperidone may indicate that side-effect considerations
are not prioritized in the planning of antipsychotic treat-
ment. A further indication is the significant rise in the pre-
scription of the FGA zuclopenthixol between admission
and discharge, as zuclopenthixol treatment has a high risk
of extrapyramidal side effects.
Younger age, inpatient treatment in the previous 12
months, as well as comorbid disorders predicted polyp-
harmacy at discharge, while inpatient treatment during
the previous 12 months predicted the prescription of FGA
at discharge. Although a comorbid diagnosis of mental
retardation had to be excluded from the regression with
FGA as the dependent variable, there is a strong covaria-
tion as we found that an FGA was prescribed in seven out
of nine discharges with a comorbid mental retardation.
Bearing in mind that our data do not provide information
about treatment resistance, a reasonable interpretation of
these findings may be that psychiatrists working in acute
inpatient units combine two or more antipsychotics when
the mental illness is complex, chronic, or remitting, while
higher symptom burden measured by GAF or HoNOS at
admission does not in itself predict either polypharmacy
or prescription of FGA. This is in line with findings in a
large study of Veteran Administration patients followed
for one year [34]. The fact that younger age predicted poly-
pharmacy is difficult to explain given treatment recom-
mendation of lower doses for first-episode patients. One
possible explanation may be that schizophrenia can be
associated with more florid symptoms in younger
patients.
The clinical significance of the predictive effects of comor-
bidity with mental retardation is questionable, at least in
our data, as the prevalence of this disorder is low. How-
ever, the finding of a very high prevalence of both polyp-
harmacy and the use of FGAs in this group is worth
noting.
The recent statement from the World Psychiatric Associa-
tion Pharmacopsychiatry Section [6] also emphasizes dos-
ing as a key variable in optimizing effectiveness of
antipsychotic treatment. Although a comprehensive sur-
vey of schizophrenia guidelines shows a great variation in
methodological quality, there was a remarkable conver-
gence in the recommendation of antipsychotic doses
between 300 and 1000 CPZ [5]. However, the authors
find in the content analysis of the guidelines that a few ref-
erence guidelines seem to have been used as primers for
others, which may have caused the convergence. The new-
est guidelines in the survey recommended lower doses,
and a possible danger of higher doses is highlighted in a
current study of sudden cardiac death among a large
cohort of users of antipsychotics [35]. An overall
increased rate of sudden cardiac death for users of antip-
sychotics versus nonusers was identified, and the risk
increased with increasing dose. The dosages of antipsy-
chotic treatment found in the present study were largely inPage 7 of 9
(page number not for citation purposes)
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tion of discharged patients was treated with doses below
300 CPZ. The interindividual variations in metabolism
and bioavailability of antipsychotics is great, and doses
below 300 CPZ can be effective, especially in first-episode
patients [36]. Other measures for comparing antipsy-
chotic equivalence exist, including Defined Daily Doses
(DDD) [37], which may give somewhat different results
[18]. Each method has its flaws, however, and there is, in
the opinion of the authors, no convincingly better
approach to compare doses in different antipsychotic
drug regimens.
Regarding prescription patterns between different hospi-
tal sites, regional differences were found. However,
because of a lack of power, it was not possible to control
this finding in a multivariate analysis. The existence of idi-
osyncratic and local drug practices is found in other stud-
ies [38].
Because data were obtained from 19 different depart-
ments with 27 different wards, there can be variations in
the way HoNOS and GAF were scored, although efforts
have been made to minimize this variation. The use of
clinical diagnoses at discharge has its limitations, as in all
studies based on clinical diagnostic work. The evaluation
at admission of seriously disturbed psychotic patients can
be difficult and can give incomplete information about
prior treatment, and although we tried to collect informa-
tion from other sources, it is possible that some informa-
tion is missing. Another limitation in the present study is
that a large portion (59.5%) of the patients in our study
was transferred to other inpatient treatment when dis-
charged from the acute ward, and thus the prescription at
the final discharge from inpatient treatment can differ
from our results. In 12% of the cases, a new prescription
was added to an antipsychotic drug that was left
unchanged during the hospitalization, and some of the
cases of antipsychotic polypharmacy may represent a
crossover period.
Conclusion
We conclude that our national survey of antipsychotic
treatment from acute inpatient treatment reveal drug reg-
imens that are to some degree at odds with current guide-
lines, with increased risk of side effects. Patients with a
high degree of recidivism, comorbid conditions, and pre-
vious inpatient treatment are especially prone to receive
deviating antipsychotic drug regimens, which has also
been found in other studies [39]. That some aspects of the
antipsychotic treatment were in total accordance with
guideline recommendations, e.g., the prescription of
monotherapy SGA to first-episode patients, could be an
indication that the guidelines are well known to the psy-
chiatrists. The reason for nonadherence to guidelines
could be vague or missing guideline recommendations for
the treatment of the most complex schizophrenic condi-
tions, as underlined by Leucht [7]. This should be a target
for future studies.
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